BioInfra Life Science Inc. (XKON:266470)

South Korea flag South Korea · Delayed Price · Currency is KRW
198.00
+10.00 (5.32%)
At close: Mar 5, 2026
-46.77%
Market Cap 3.92B
Revenue (ttm) 1.78B
Net Income (ttm) -3.59B
Shares Out 21.67M
EPS (ttm) -266.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,449
Average Volume 8,454
Open 216.00
Previous Close 188.00
Day's Range 168.00 - 216.00
52-Week Range 139.00 - 459.00
Beta -0.35
RSI 34.57
Earnings Date n/a

About BioInfra Life Science

BioInfra Life Science Inc., a healthcare company, develops cancer gene treatments and technologies that monitor the possibility of metastasis and recurrence in blood for cancer patients in South Korea. It provides cancer screening test technology service, cancer biomarker research, in-vitro diagnostics medical devices, and targeted drug delivery systems for cancer treatment. The company was founded in 2001 and is headquartered in Seoul, South Korea. [Read more]

Industry Surgical and Medical Instruments and Apparatus
Founded 2001
Country South Korea
Stock Exchange Korea New Exchange
Ticker Symbol 266470
Full Company Profile

Financial Performance

In 2019, BioInfra Life Science's revenue was 1.87 billion, an increase of 20.83% compared to the previous year's 1.55 billion. Losses were -3.28 billion, -13.88% less than in 2018.

Financial Statements

News

There is no news available yet.